North Carolina is currently home to 2655 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Durham, Charlotte, Winston-Salem and Chapel Hill. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Accuracy Performance Verification of the INVOS™ PM7100 System in Adults
NCT06581835
Recruiting
Prospective, observational, post-market, verification study to ensure compliance to the ISO 80601-2-85:2021 standard
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
05/06/2025
Locations: Duke University, Durham, North Carolina
Conditions: Oxygen Saturation
Register for Updates
A Study of Obexelimab in Patients With Systemic Lupus Erythematosus
NCT06559163
Recruiting
This study aims to examine the efficacy and safety of obexelimab in participants with systemic lupus erythematosus (SLE).
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
05/06/2025
Locations: DJL Clinical Research PLLC, Charlotte, North Carolina
Conditions: Systemic Lupus Erythematosus
Register for Updates
MB-105 in Patients With CD5 Positive T-cell Lymphoma
NCT06534060
Recruiting
This is a single arm, two-stage, Phase 2, open-label, multicenter study of MB-105 in patients with CD5 Positive (CD5+) Relapsed / Refractory T-cell Lymphoma (r/r TCL). This study will apply a Simon two-stage optimal design.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/06/2025
Locations: University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
Conditions: Lymphoma, T-Cell
Register for Updates
Clinical Trial of Upfront Haploidentical or Unrelated Donor BMT to Restore Normal Hematopoiesis in Aplastic Anemia
NCT06517641
Recruiting
BMT CTN 2207 will investigate the use of marrow transplantation for treatment of severe aplastic anemia that has not previously been treated.
Gender:
ALL
Ages:
Between 3 years and 75 years
Trial Updated:
05/06/2025
Locations: Levine Cancer Institute, Charlotte, North Carolina
Conditions: Severe Aplastic Anemia
Register for Updates
Belumosudil to Block Chronic Lung Allograft Dysfunction (CLAD) in High Risk Lung Transplant Recipients
NCT06476132
Recruiting
The purpose of this study is to see if taking the study drug, Belumosudil, for 52 weeks in addition to your usual care and medication, will prevent Chronic Lung Allograft Dysfunction (CLAD) in participants who have a lung biopsy that shows evidence of rejection or inflammation to the transplanted lung(s). For this study, biopsies that show evidence of Acute Rejection (AR), Lymphocytic Bronchiolitis (LB), Organizing Pneumonia (OP) or Acute Lung Injury (ALI) are referred to as "Qualifying Biopsies... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
05/06/2025
Locations: Duke University (Site #: 71139), Durham, North Carolina
Conditions: Lung Transplant
Register for Updates
A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss and Fat Loss
NCT06299098
Recruiting
This study is researching experimental drugs called trevogrumab and garetosmab (called "study drugs") in combination with another drug, semaglutide (Wegovy®). This study will be done in 3 parts, Part A, Part B, and Part C where different study drugs will be tested. Part A of the study is focused on healthy participants. Part B and C of the study is focused on participants with obesity. The aim of Part A of the study is to see how safe and tolerable the study drug is in healthy participants. Th... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
05/06/2025
Locations: Accellacare Clinical Research, Raleigh Medical Group, Raleigh, North Carolina
Conditions: Obesity
Register for Updates
A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors
NCT05848739
Recruiting
This is an open-label, two-part, phase 1-2 study designed to determine the safety, tolerability, PK, pharmacodynamics (PD), and proof-of-concept efficacy of ST316 administered IV in subjects with selected advanced solid tumors likely to harbor abnormalities of the WNT/β-catenin signaling pathway. The study consists of two phases: a phase 1 dose escalation/regimen exploration phase and a phase 2 expansion phase.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/06/2025
Locations: Duke Universtiy, Durham, North Carolina
Conditions: Colon Cancer, Metastatic Colon Cancer
Register for Updates
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants
NCT05831111
Recruiting
The purpose of this study is to evaluate the safety and reactogenicity of mRNA-1195 in healthy participants.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
05/06/2025
Locations: Eximia Clinical Research, Raleigh, North Carolina
Conditions: Epstein-Barr Virus Infection
Register for Updates
Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHD
NCT04781140
Recruiting
This study will evaluate the efficacy and safety of SPN-812 (viloxazine extended release) in children 4 to 5 years of age with ADHD.
Gender:
ALL
Ages:
Between 48 months and 69 months
Trial Updated:
05/06/2025
Locations: Duke University, Durham, North Carolina
Conditions: Attention-Deficit/Hyperactivity Disorder
Register for Updates
Triathlon All-Polyethylene Tibia Outcomes Study
NCT04636190
Recruiting
The purpose of this study is to evaluate the clinical functional results of the Triathlon All-Polyethylene Tibia Knee Device.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/06/2025
Locations: Duke University Medical Center, Durham, North Carolina
Conditions: Arthropathy of Knee, Replacement, Knee Arthritis
Register for Updates
Project Talk Trial: Engaging Underserved Communities in End-of-life Conversations
NCT04612738
Recruiting
Compared to the general population, individuals from underserved communities are more likely to receive low quality end-of-life care and unwanted, costly and burdensome treatments due in part to a lack of advance care planning (ACP; the process of discussing wishes for end-of-life care with loved ones/clinicians and documenting them in advance directives). This study will use existing, trusted, and respected social networks to evaluate two conversation-based tools intended to engage underserved... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/06/2025
Locations: Greater Vision United Methodist Church, Huntersville, North Carolina
Conditions: Advance Care Planning, Advance Directives, Terminal Illness, Chronic Illness, Communication
Register for Updates
A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata
NCT06873945
Recruiting
The purpose of the study is to learn about the safety and effects of the study medicine (called ritlecitinib) for the treatment of alopecia areata. Alopecia areata is a disease that causes hair loss on the scalp, face, and areas of the body. Ritlecitinib is approved in many countries at a dose of 50 mg (milligram) taken by mouth once a day for the treatment of patients 12 years and older with severe alopecia areata. This study will look at both the 50 mg dose and a 100 mg dose. This study is s... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
05/05/2025
Locations: DJL Clinical Research, PLLC, Charlotte, North Carolina
Conditions: Alopecia Areata
Register for Updates